Summary:
Key Takeaways:
- Hydrophilic peptide encapsulation in PLGA microspheres is one of pharma’s hardest formulation challenges — high water solubility causes rapid drug leaching during microsphere formation.
- ResolveMass Laboratories successfully encapsulated a model hydrophilic peptide (MW ~1,800 Da) achieving >72% encapsulation efficiency and 28-day sustained release.
- Three core strategies resolved the challenge: double emulsion (W/O/W) process optimisation, peptide salt conversion, and pore-sealing PEGylation.
- Critical process parameters — inner aqueous phase volume, homogenisation speed, organic solvent selection, and hardening bath temperature — were systematically screened using DoE.
- Release kinetics showed a controlled biphasic profile: <10% burst release followed by near-zero-order release over 28 days.
- Analytical tools used: HPLC, DLS, SEM, DSC, and in vitro release testing — demonstrating full characterisation capability at ResolveMass.
- This case study demonstrates how a CRO with deep formulation expertise can de-risk hydrophilic peptide PLGA microsphere projects for pharma and biotech clients.
1: Introduction: Why Hydrophilic Peptide Encapsulation in PLGA Microspheres Is So Difficult
Hydrophilic Peptide Encapsulation in PLGA Microspheres is inherently difficult because the water-loving nature of peptides directly opposes the hydrophobic environment needed to form stable PLGA microspheres. The result: poor entrapment, high burst release, and inconsistent therapeutic profiles.
Peptide therapeutics have emerged as one of the fastest-growing segments in pharmaceutical development. From GLP-1 analogues to antimicrobial peptides and immunomodulatory sequences, these molecules offer remarkable target selectivity. However, their short plasma half-lives and the need for frequent injections remain major clinical barriers — barriers that sustained-release microsphere formulations are designed to overcome.
PLGA (poly(lactic-co-glycolic acid)) microspheres represent the gold standard for injectable sustained-release delivery. PLGA is FDA-approved, biodegradable, and well-characterised in terms of safety and degradation kinetics. When loaded correctly, microspheres can maintain therapeutic drug concentrations for days to months from a single injection.
Yet encapsulating hydrophilic peptides inside PLGA matrices remains one of formulation science’s most stubborn challenges. At ResolveMass Laboratories Inc., we have spent years developing the process expertise to crack this problem — and this case study documents one such project in full detail.
Core Challenges at a Glance:
| Challenge | Root Cause | Impact on Product Quality |
|---|---|---|
| Poor encapsulation efficiency | Peptide partitions into outer aqueous phase during emulsification | Low drug loading; wasted API |
| High burst release | Drug concentrated near microsphere surface | Toxic peak plasma levels; poor PK profile |
| Peptide aggregation | Aqueous-organic interface denaturing | Loss of bioactivity; immunogenic risk |
| Broad particle size distribution | Unstable emulsion droplets | Variable release kinetics batch-to-batch |
| Incomplete PLGA encapsulation | Water pores bridging through matrix | Premature release via diffusion channels |
2: Project Background: The Peptide and the Objective
The target peptide was a synthetic analogue with a molecular weight of approximately 1,800 Da, logP of −2.4, and aqueous solubility exceeding 50 mg/mL — placing it firmly in the “highly hydrophilic” category. The client’s clinical goal was a once-monthly subcutaneous injection replacing a twice-daily oral dose.
Target Product Profile (TPP)
- Particle size: 10–50 µm (injectable via 21G needle)
- Encapsulation efficiency (EE): ≥60%
- Burst release at 24 h: ≤15% of total drug
- Cumulative release at Day 28: ≥80%
- Peptide integrity post-encapsulation: ≥95% (by RP-HPLC purity)
- Sterility-compatible process (aseptic manufacturing pathway)
These specifications demanded a formulation approach that would not just encapsulate the peptide but protect it from the organic solvent interface, control its release rate with precision, and do so at a scale amenable to GMP transition.
3: Formulation Strategy: The Double Emulsion (W/O/W) Approach
The double emulsion (W/O/W) method is the primary technique used for hydrophilic peptide encapsulation in PLGA microspheres. The peptide is dissolved in an inner aqueous phase, emulsified into an organic PLGA solution to form a primary emulsion (W/O), then re-emulsified into an outer aqueous phase containing a stabiliser to form microspheres.
While conceptually straightforward, achieving high encapsulation efficiency and low burst release simultaneously requires precise control at every step. Our formulation scientists at ResolveMass systematically optimised each stage.
3.1 Key Formulation Variables Screened
| Process Variable | Range Tested | Optimised Value | Effect on EE |
|---|---|---|---|
| Inner aqueous phase volume (W1) | 1–10% v/v of organic phase | 3% v/v | ↓ volume → ↑ EE |
| PLGA concentration in organic phase | 5–20% w/v in DCM | 10% w/v | ↑ conc. → ↑ EE, ↑ viscosity |
| Organic solvent | DCM, EtAc, DCM:EtAc blends | DCM:EtAc (3:1) | Blend ↑ EE, ↓ burst |
| Primary homogenisation speed | 5,000–20,000 rpm | 10,000 rpm / 60 s | Optimal droplet size |
| PVA concentration (outer phase) | 0.5–5% w/v | 1% w/v | ↑ PVA → ↑ EE up to 1% |
| Hardening bath temperature | RT vs 4°C | 4°C | ↓ temp → ↓ burst release |
| Peptide salt form | Free acid vs acetate vs HCl | Acetate salt | ↑ EE by ~18% |
3.2 The Role of Peptide Salt Conversion
One of the most impactful — and often overlooked — strategies for improving encapsulation efficiency is converting the peptide from its free acid form to an ion-paired salt. By forming an ion pair with a hydrophobic counter-ion (in our case, pamoate), we effectively reduce the aqueous solubility of the peptide, reducing its tendency to partition into the outer aqueous phase during secondary emulsification.
In our experiments, pamoate salt conversion increased encapsulation efficiency from 51% to 69% before any other process changes were made. This single intervention alone nearly met the minimum EE target.
3.3 PEGylated PLGA: Sealing the Pores
A persistent problem with PLGA microspheres is the formation of aqueous pore channels during solvent extraction. These channels allow rapid diffusion of hydrophilic drugs, directly contributing to burst release. By blending PEG-PLGA (5% w/w) into the polymer matrix, we achieved surface PEGylation that physically seals these channels during hardening, reducing burst release from 22% to 8% without compromising total release at 28 days.
4: Manufacturing Process: Step-by-Step Protocol Overview
Each manufacturing step was optimised and documented at ResolveMass under controlled conditions. Below is a summary of the finalised process.
- Step 1 — Peptide Preparation: Dissolve peptide acetate salt in ultrapure water (50 mg/mL). Filter sterilise (0.22 µm). Keep at 4°C.
- Step 2 — PLGA Solution: Dissolve PLGA (Mw 40–75 kDa, 50:50 LA:GA) and PEG-PLGA at 10% w/v in DCM:EtAc (3:1 v/v).
- Step 3 — Primary Emulsification (W/O): Add 0.3 mL peptide solution to 10 mL PLGA organic solution. Homogenise at 10,000 rpm for 60 seconds using a probe homogeniser. Maintain ice bath.
- Step 4 — Secondary Emulsification (W/O/W): Transfer primary emulsion into 100 mL of 1% PVA aqueous solution pre-cooled to 4°C. Stir at 500 rpm for 3 hours (solvent evaporation).
- Step 5 — Hardening and Collection: Continue stirring at 4°C for additional 1 hour. Collect microspheres by centrifugation (3,000 × g, 10 min). Wash 3× with ultrapure water.
- Step 6 — Lyophilisation: Freeze-dry with 5% mannitol as cryoprotectant. −80°C pre-freeze, primary drying at −40°C/100 mTorr, secondary drying at 25°C.
5: Analytical Characterisation: Full Battery Testing
Characterisation is where formulation success is proven. At ResolveMass Laboratories, we deployed a comprehensive analytical suite to fully characterise the optimised microsphere formulation.
5.1 Particle Size and Morphology
- Dynamic Light Scattering (DLS): Z-average diameter: 32.4 µm ± 3.8 µm. PDI: 0.18 (acceptable for injectable microspheres).
- Scanning Electron Microscopy (SEM): Smooth, spherical morphology confirmed. No visible surface pores or cracks. Lyophilised samples showed minimal particle aggregation.
- Laser Diffraction (Malvern Mastersizer): D10 = 18 µm, D50 = 31 µm, D90 = 52 µm — within the 10–50 µm injectable range.
5.2 Encapsulation Efficiency and Drug Loading
Microspheres were dissolved in DMSO, diluted in mobile phase, and analysed by RP-HPLC (C18 column, UV detection at 214 nm).
- Encapsulation Efficiency (EE): 72.3% ± 4.1%
- Actual Drug Loading: 6.8% w/w (target: ≥5%)
- Peptide Purity Post-encapsulation: 96.2% (by area normalisation)
5.3 In Vitro Release Profile
Release testing was conducted in PBS (pH 7.4, 37°C, 100 rpm orbital shaker). Samples collected at Days 1, 3, 7, 14, 21, and 28.
| Time Point | Cumulative Release (%) | Interpretation |
|---|---|---|
| Day 1 (Burst) | 8.4% | Well below 15% target — minimal burst |
| Day 3 | 16.2% | Steady diffusion phase begins |
| Day 7 | 31.5% | Near-zero-order kinetics confirmed |
| Day 14 | 54.8% | Matrix erosion contributing to release |
| Day 21 | 71.3% | PLGA degradation accelerating |
| Day 28 | 83.7% | Meets ≥80% target — complete |
5.4 Thermal Analysis (DSC)
Differential Scanning Calorimetry confirmed peptide amorphous dispersion within the PLGA matrix — no sharp peptide melting endotherm was observed in the microsphere thermogram, indicating successful molecular-level encapsulation rather than surface adsorption or crystalline domains.
6: Design of Experiments (DoE): How ResolveMass Achieves Reproducibility
Systematic optimisation — not trial-and-error — is what separates reliable formulation development from repeated failure. ResolveMass employs Design of Experiments (DoE) methodology as a cornerstone of our development workflow.
For this project, a Definitive Screening Design (DSD) was used in the initial screening phase (8 factors, 17 runs), followed by a Central Composite Design (CCD) for optimisation of the top 4 critical process parameters.
Critical Process Parameters (CPPs) Identified by DoE
- Inner aqueous phase volume ratio: Largest effect on EE — lower ratios strongly favoured encapsulation.
- Primary homogenisation speed and time: Directly controlled droplet size and uniformity of the primary emulsion.
- PLGA molecular weight and end-group chemistry: Acid-terminated PLGA (vs. ester-terminated) enhanced peptide retention.
- Hardening temperature: Lower temperature during solvent evaporation reduced burst release significantly.
Using the DoE model, we identified an optimised design space where EE >65% and burst release <12% could be reliably achieved. This design space was documented as part of the Quality by Design (QbD) package — an asset directly transferable to GMP manufacturing.
7: Results Summary and Comparison to Target Product Profile
| Parameter | Target | Achieved | Status |
|---|---|---|---|
| Particle size (D50) | 10–50 µm | 31 µm | ✓ Pass |
| Encapsulation Efficiency | ≥60% | 72.3% | ✓ Pass |
| Burst Release (24 h) | ≤15% | 8.4% | ✓ Pass |
| Cumulative Release (Day 28) | ≥80% | 83.7% | ✓ Pass |
| Peptide Purity Post-encapsulation | ≥95% | 96.2% | ✓ Pass |
| Batch-to-batch EE CV | <10% | 5.7% | ✓ Pass |
All six parameters met or exceeded the Target Product Profile specifications. This outcome demonstrates that with the right formulation strategy, analytical rigour, and process understanding, the challenge of hydrophilic peptide encapsulation in PLGA microspheres is entirely solvable.
8: Lessons Learned: Critical Success Factors
Based on the outcomes of this project, the following factors were most critical to success:
- Ion pairing before encapsulation: Converting hydrophilic peptides to hydrophobic salt forms (e.g., pamoate) is a highly effective and underutilised strategy that significantly improves partitioning behaviour.
- Minimise the inner aqueous phase volume: Less water in W1 means less drug leaching during W/O emulsification. This is counterintuitive but one of the most impactful levers available.
- PEG-PLGA blending for pore sealing: Surface PEGylation is a practical and scalable approach to reducing burst release without altering core PLGA polymer chemistry.
- Temperature-controlled hardening: Conducting the solvent evaporation step at 4°C rather than room temperature meaningfully reduces burst release — a simple and scalable intervention.
- DoE over OFAT: One-factor-at-a-time approaches miss interaction effects. DoE compressed our development timeline by approximately 40% compared to conventional approaches.
9: About ResolveMass Laboratories Inc.: Our Formulation Science Expertise
ResolveMass Laboratories Inc. is a Canadian contract research and development organisation (CRO/CDMO) specialising in advanced drug delivery formulations, with deep expertise in:
- Polymeric microsphere and nanoparticle formulation (PLGA, PCL, PLA, chitosan)
- Peptide and protein drug delivery systems
- Lipid-based drug delivery (liposomes, SLN, LNP)
- Quality by Design (QbD) and Design of Experiments (DoE) workflows
- Analytical method development and validation (HPLC, GPC, DLS, SEM, DSC)
- IND-enabling formulation development and GMP-ready technology transfer
Our scientists bring decades of combined experience from academic research, regulatory submissions, and pharmaceutical industry formulation groups. We operate at the intersection of science and regulatory strategy — ensuring that every formulation we develop is not only technically robust but positioned for seamless scale-up and regulatory review.
Every project at ResolveMass is approached with the same rigour, transparency, and client-centricity demonstrated in this case study. We do not outsource your problem — we solve it, in-house, with documented science.
Conclusion:
Hydrophilic Peptide Encapsulation in PLGA Microspheres demands a multi-factorial, science-driven approach — and this case study shows exactly what that looks like in practice. By combining ion-pairing chemistry, optimised double-emulsion process parameters, PEG-PLGA matrix engineering, and DoE-guided development, ResolveMass Laboratories achieved a formulation that met every target in the product profile.
The result was a 28-day sustained-release microsphere with 72.3% encapsulation efficiency, <10% burst release, and demonstrated peptide integrity — a formulation ready for scale-up, GMP transition, and IND-enabling studies.
If you are developing a peptide therapeutic and facing the encapsulation efficiency, burst release, or stability challenges described in this case study, our team at ResolveMass is ready to help. We offer feasibility studies, full formulation development programmes, and technology transfer support.
Frequently Asked Questions:
Hydrophilic peptides tend to dissolve in aqueous phases and can easily diffuse out of the microsphere during manufacturing. This often leads to low encapsulation efficiency, poor drug loading, and inconsistent release profiles. The hydrophobic nature of PLGA further complicates peptide retention within the polymer matrix. Specialized formulation strategies are therefore required to achieve optimal encapsulation. Process parameters and polymer characteristics also play a significant role in formulation success.
Encapsulation efficiency is influenced by several variables, including peptide solubility, PLGA molecular weight, polymer concentration, emulsion stability, solvent selection, and processing conditions. The ratio of internal to external aqueous phases can also impact peptide leakage during manufacturing. Optimizing these parameters helps maximize drug loading and minimize product loss. Analytical testing is essential to identify critical formulation variables.
The water-in-oil-in-water (W/O/W) double-emulsion solvent evaporation technique is the most widely used method for encapsulating hydrophilic peptides. This approach allows peptides to be dispersed within an internal aqueous phase before being trapped inside the PLGA matrix. Careful optimization of emulsification conditions is required to reduce peptide diffusion and improve encapsulation efficiency. The method is widely used for developing long-acting injectable formulations.
Burst release can be reduced by increasing polymer concentration, optimizing particle hardening conditions, controlling microsphere porosity, and minimizing surface-associated peptide. Proper polymer selection and process optimization help distribute the peptide more uniformly within the microsphere matrix. Stabilizers may also improve peptide retention during manufacturing. Reducing burst release is important for maintaining predictable therapeutic performance.
PLGA properties such as molecular weight, lactide-to-glycolide ratio, viscosity, and end-group chemistry directly affect encapsulation efficiency and release behavior. Higher molecular weight polymers often improve peptide retention and extend drug release duration. Selecting the appropriate polymer grade can significantly reduce peptide leakage and improve formulation stability. Polymer screening is typically an important part of formulation development.
Common analytical techniques include HPLC, LC-MS/MS, size-exclusion chromatography (SEC), scanning electron microscopy (SEM), particle size analysis, differential scanning calorimetry (DSC), and in vitro release testing. These methods help evaluate peptide content, purity, particle morphology, release kinetics, and product stability. Comprehensive characterization ensures formulation quality and regulatory compliance.
Yes, high encapsulation efficiency can be achieved through careful optimization of formulation composition, polymer selection, emulsion parameters, and stabilizer use. Modern formulation approaches routinely achieve encapsulation efficiencies above 70–80% for many peptide products. Success depends on understanding the physicochemical properties of the peptide and controlling critical process variables.
Regulatory agencies expect comprehensive characterization of particle size, drug loading, release kinetics, stability, impurities, and manufacturing consistency. Developers must demonstrate product quality, safety, and reproducibility through validated analytical methods and stability studies. Regulatory submissions should include detailed information on formulation development, process controls, and product performance. Early analytical and formulation planning can significantly streamline regulatory approval pathways.
Reference
- Marinelli L, Ciulla M, Ritsema JA, van Nostrum CF, Cacciatore I, Dimmito MP, Palmerio F, Orlando G, Robuffo I, Grande R, Puca V. Preparation, characterization, and biological evaluation of a hydrophilic peptide loaded on PEG-PLGA nanoparticles. Pharmaceutics. 2022 Aug 29;14(9):1821.https://www.mdpi.com/1999-4923/14/9/1821
- Mohammadi-Samani S, Taghipour B. PLGA micro and nanoparticles in delivery of peptides and proteins; problems and approaches. Pharmaceutical development and technology. 2015 May 19;20(4):385-93.https://www.tandfonline.com/doi/abs/10.3109/10837450.2014.882940
- Jang W, Bong KW. Strategies for Loading and Releasing Peptide Therapeutics in Biodegradable Carriers. Advanced Functional Materials. 2026 Mar 21:e31987.https://advanced.onlinelibrary.wiley.com/doi/abs/10.1002/adfm.202531987
- Bee SL, Hamid ZA, Mariatti M, Yahaya BH, Lim K, Bee ST, Sin LT. Approaches to improve therapeutic efficacy of biodegradable PLA/PLGA microspheres: a review. Polymer reviews. 2018 Jul 3;58(3):495-536.https://www.tandfonline.com/doi/abs/10.1080/15583724.2018.1437547
- Taluja A, Youn YS, Bae YH. Novel approaches in microparticulate PLGA delivery systems encapsulating proteins. Journal of Materials Chemistry. 2007;17(38):4002-14.https://pubs.rsc.org/en/content/articlehtml/2007/jm/b706939a
- Ramazani F, Chen W, Van Nostrum CF, Storm G, Kiessling F, Lammers T, Hennink WE, Kok RJ. Strategies for encapsulation of small hydrophilic and amphiphilic drugs in PLGA microspheres: state-of-the-art and challenges. International journal of pharmaceutics. 2016 Feb 29;499(1-2):358-67.https://www.sciencedirect.com/science/article/pii/S0378517316300205
- Lagreca E, Onesto V, Di Natale C, La Manna S, Netti PA, Vecchione R. Recent advances in the formulation of PLGA microparticles for controlled drug delivery. Progress in biomaterials. 2020 Dec;9(4):153-74.https://link.springer.com/article/10.1007/s40204-020-00139-y
- Andhariya JV, Jog R, Shen J, Choi S, Wang Y, Zou Y, Burgess DJ. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres. Journal of controlled release. 2019 Aug 28;308:1-3.https://www.sciencedirect.com/science/article/pii/S0168365919304006
About the Author
